Is this you? Create Your Porfile
Avatar

Steven K. Laughlin

Procter & Gamble

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Steven K. Laughlin is active.

Explore More

Publication

Featured researches published by Steven K. Laughlin.

Bioorganic & Medicinal Chemistry Letters | 2003

The development of new triazole based inhibitors of tumor necrosis factor-α (TNF-α) production

Steven K. Laughlin; Michael Philip Clark; Jane Far-Jine Djung; Adam Golebiowski; Todd A. Brugel; Mark Sabat; Roger G. Bookland; Matthew J. Laufersweiler; John C. VanRens; Jennifer A. Townes; Biswanath De; Lily C. Hsieh; Susan C. Xu; Richard Walter; Marlene Mekel; Michael J. Janusz

4-Aryl-3-pyridyl and 4-aryl-3-pyrimidinyl based tumor necrosis factor-alpha (TNF-alpha) inhibitors, which contain a novel isoxazolone five-membered heterocyclic core are described. Many showed sub-micromolar activity against lipopolysaccharide-induced TNF-alpha production.

Journal of Medicinal Chemistry | 2004

Development of orally bioavailable bicyclic pyrazolones as inhibitors of tumor necrosis factor-α production

Michael Philip Clark; Steven K. Laughlin; Matthew J. Laufersweiler; Roger G. Bookland; Todd A. Brugel; Adam Golebiowski; Mark Sabat; Jennifer A. Townes; John C. VanRens; Jane Far-Jine Djung; Michael G. Natchus; Biswanath De; Lily C. Hsieh; Susan C. Xu; Rick L. Walter; Marlene Mekel; S.A. Heitmeyer; Kimberly K. Brown; Karen Juergens; Yetunde Olabisi Taiwo; Michael J. Janusz

Bioorganic & Medicinal Chemistry Letters | 2007

Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3)

Michael Philip Clark; Kelly M. George; Roger G. Bookland; Steven K. Laughlin; Kumar D. Thakur; Wenlin Lee; Jan Richard Davis; Ed J. Cabrera; Todd A. Brugel; John C. VanRens; Matthew J. Laufersweiler; Jennifer A. Maier; Mark Sabat; Adam Golebiowski; Vijay Easwaran; Mark E. Webster; Biswanath De; George Zhang

Bioorganic & Medicinal Chemistry Letters | 2006

Development of pyrimidine-based inhibitors of Janus tyrosine kinase 3.

Kumar D. Thakur; Michael Philip Clark; Steven K. Laughlin; Kelly M. George; Roger G. Bookland; Jan Richard Davis; Edward J. Cabrera; Vijay Easwaran; Biswanath De; Y. George Zhang

Archive | 2001

Heterocyclic side chain containing, n-substituted metalloprotease inhibitors

Stanislaw Pikul; Norman Eugene Ohler; Neil Gregory Almstead; Steven K. Laughlin; Michael George Natchus; Biswanath De; Paul Mitchell Hershberger

Bioorganic & Medicinal Chemistry Letters | 2006

Development of N-2,4-pyrimidine-N-phenyl-N′-phenyl ureas as inhibitors of tumor necrosis factor alpha (TNF-α) synthesis. Part 1

Todd A. Brugel; Jennifer A. Maier; Michael Philip Clark; Mark Sabat; Adam Golebiowski; Roger G. Bookland; Matthew J. Laufersweiler; Steven K. Laughlin; John C. VanRens; Biswanath De; Lily C. Hsieh; Marlene Mekel; Michael J. Janusz

Bioorganic & Medicinal Chemistry Letters | 2005

The development of monocyclic pyrazolone based cytokine synthesis inhibitors

Adam Golebiowski; Jennifer A. Townes; Matthew J. Laufersweiler; Todd A. Brugel; Michael Philip Clark; Cynthia Monesa Clark; Jane Far-Jine Djung; Steven K. Laughlin; Mark Sabat; Roger G. Bookland; John C. VanRens; Biswanath De; Lily C. Hsieh; Michael J. Janusz; Richard Walter; Mark E. Webster; Marlene Mekel

Bioorganic & Medicinal Chemistry Letters | 2004

The development of novel inhibitors of tumor necrosis factor-α (TNF-α) production based on substituted [5,5]-bicyclic pyrazolones

Matthew J. Laufersweiler; Todd A. Brugel; Michael Philip Clark; Adam Golebiowski; Roger G. Bookland; Steven K. Laughlin; Mark Sabat; Jennifer A. Townes; John C. VanRens; Biswanath De; Lily C. Hsieh; S.A. Heitmeyer; Karen Juergens; Kimberly K. Brown; Marlene Mekel; Richard Walter; Michael J. Janusz

Bioorganic & Medicinal Chemistry Letters | 2006

The development of novel C-2, C-8, and N-9 trisubstituted purines as inhibitors of TNF-alpha production.

Mark Sabat; John C. VanRens; Michael Philip Clark; Todd A. Brugel; Jennifer A. Maier; Roger G. Bookland; Matthew J. Laufersweiler; Steven K. Laughlin; Adam Golebiowski; Biswanath De; Lily C. Hsieh; Richard Walter; Marlene Mekel; Michael J. Janusz

Bioorganic & Medicinal Chemistry Letters | 2006

Development of N-2,4-pyrimidine-N-phenyl-N'-alkyl ureas as orally active inhibitors of tumor necrosis factor alpha (TNF-α) synthesis. Part 2

Jennifer A. Maier; Todd A. Brugel; Michael Philip Clark; Mark Sabat; Adam Golebiowski; Roger G. Bookland; Matthew J. Laufersweiler; Steven K. Laughlin; John C. VanRens; Biswanath De; Lily C. Hsieh; Kimberly K. Brown; Karen Juergens; Richard Walter; Michael J. Janusz

Explore More

Collaboration

Dive into the Steven K. Laughlin's collaboration.

Top Co-Authors
Avatar

Biswanath De

Procter

View shared research outputs
Top Co-Authors
Avatar

Michael Philip Clark

Procter

View shared research outputs
Top Co-Authors
Avatar

Adam Golebiowski

Procter

View shared research outputs
Top Co-Authors
Avatar

Mark Sabat

Procter

View shared research outputs
Top Co-Authors
Avatar

Roger G. Bookland

Procter

View shared research outputs
Top Co-Authors
Avatar

Todd A. Brugel

Procter

View shared research outputs
Top Co-Authors
Avatar

John C. VanRens

Procter

View shared research outputs
Top Co-Authors
Avatar

Matthew J. Laufersweiler

Procter

View shared research outputs
Top Co-Authors
Avatar

Lily C. Hsieh

Procter

View shared research outputs
Top Co-Authors
Avatar

Michael J. Janusz

Procter

View shared research outputs
Explore More
Researchain Logo
Decentralizing Knowledge